Sugar-sweetened beverages increase risk of death from obesity-related cancer

In a large study led by researchers at the American Cancer Society (ACS), men and women who drank two or more servings of sugar-sweetened beverages (SSB) per day, compared to people who never drank, had a five percent increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial and kidney cancer. These results appear to be related to the higher body mass index (BMI) of the participants who regularly drank SSBs. BMI is a measure of body size, combining a person's weight with their height, showing whether a person has a healthy weight. The study was published today in Cancer, Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Unfortunately, Americans exceed recommended limits on sugar consumption by the U.S. Dietary Guidelines, and sugar-sweetened beverages are known risk factors for weight gain, being overweight, and obesity. Our findings further support the recommendation to limit consumption of sugar-sweetened beverages included in the ACS Guideline on Nutrition and Physical Activity for Cancer Prevention to help decrease the risk of disease."

Dr. Marjorie McCullough, senior scientific director, epidemiology research at the American Cancer Society and lead author of the study

For the study, researchers examined the associations of SSBs and artificially sweetened beverages (ASB) with mortality from all cancers combined, obesity-related cancers combined, and 20 cancer types, among men and women in the Cancer Prevention Study-II (CPS-II) prospective cohort. In 1982, more than nine hundred thousand cancer-free participants provided information on usual SSB and ASB consumption. Deaths were identified through 2016. Multivariable Cox proportional hazards regression models examined associations of beverage types with cancer mortality, without and with BMI adjustment.

During the study follow-up, 135,093 CPS-II participants died from cancer. Results showed that consumption by men and women of greater than two SSB drinks a day versus people who never drank was not associated with all-cancer mortality, but was associated with increased risk of obesity-related cancers combined, which became null after adjustment for BMI. SSBs were associated with increased mortality from colorectal, and kidney cancers, which remained after BMI adjustment. A positive association of ASB consumption with obesity-related cancers was null after controlling for BMI; however, an increased risk of pancreatic cancer remained even with BMI adjustment. Researchers add associations between ASB consumption and increased pancreatic cancer risk merit further study.

"Future research should consider the role of BMI in studies of sweetened beverages and cancer risk," McCullough adds. "These results should inform public policy regarding sweetened beverage consumption to decrease the risk of cancer for men and women in the U.S."

McCullough also adds while most artificial sweeteners are generally thought to be safe, artificial sweetener use in the U.S. is increasing and whether these exposures are associated with cancer risk in humans remains of interest.

Dr. Alpa Patel is senior author of the study.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research unveils mechanism behind deadly neuroendocrine prostate cancer